Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection — DISCOVER  

Pre-Exposure Prophylaxis of HIV-1 Infection Clinical Trial

Official title: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Status Active, not recruiting

Clinical Trial Summary

The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Communicable Diseases
• HIV Infections
• Infections
• Pre-Exposure Prophylaxis of HIV-1 Infection

• NCT number: NCT02842086
• Study type: Interventional
• Source: Gilead Sciences
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: September 2, 2016
• Completion date: September 2027